EP1303287A4 - Mhc peptides over-expressed on prostate cancer cells and methods of use - Google Patents

Mhc peptides over-expressed on prostate cancer cells and methods of use

Info

Publication number
EP1303287A4
EP1303287A4 EP01942207A EP01942207A EP1303287A4 EP 1303287 A4 EP1303287 A4 EP 1303287A4 EP 01942207 A EP01942207 A EP 01942207A EP 01942207 A EP01942207 A EP 01942207A EP 1303287 A4 EP1303287 A4 EP 1303287A4
Authority
EP
European Patent Office
Prior art keywords
expressed
methods
cancer cells
prostate cancer
peptides over
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01942207A
Other languages
German (de)
French (fr)
Other versions
EP1303287A1 (en
Inventor
Forest White
Donald F Hunt
Jeffrey Shabanowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Virginia UVA
University of Virginia Patent Foundation
Argonex Pharmaceuticals Inc
Original Assignee
University of Virginia UVA
University of Virginia Patent Foundation
Argonex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia UVA, University of Virginia Patent Foundation, Argonex Pharmaceuticals Inc filed Critical University of Virginia UVA
Publication of EP1303287A1 publication Critical patent/EP1303287A1/en
Publication of EP1303287A4 publication Critical patent/EP1303287A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP01942207A 2000-06-16 2001-06-15 Mhc peptides over-expressed on prostate cancer cells and methods of use Withdrawn EP1303287A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21221300P 2000-06-16 2000-06-16
US21216500P 2000-06-16 2000-06-16
US212213P 2000-06-16
US212165P 2000-06-16
PCT/US2001/019207 WO2001097827A1 (en) 2000-06-16 2001-06-15 Mhc peptides over-expressed on prostate cancer cells and methods of use

Publications (2)

Publication Number Publication Date
EP1303287A1 EP1303287A1 (en) 2003-04-23
EP1303287A4 true EP1303287A4 (en) 2006-02-08

Family

ID=26906839

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01942207A Withdrawn EP1303287A4 (en) 2000-06-16 2001-06-15 Mhc peptides over-expressed on prostate cancer cells and methods of use

Country Status (3)

Country Link
EP (1) EP1303287A4 (en)
AU (1) AU2001275490A1 (en)
WO (1) WO2001097827A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE385503T1 (en) 1999-06-28 2008-02-15 Inter K Pty Ltd METHOD FOR MODULATING INTEGRIN-MEDIATED CELL ACTIVITY AND REAGENTS SUITABLE FOR THIS
AUPR230500A0 (en) 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
JP5898495B2 (en) * 2008-10-06 2016-04-06 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア Methods and systems for predicting misfolded protein epitopes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033888A1 (en) * 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
US5846810A (en) * 1994-10-28 1998-12-08 Kyowa Hakko Kogyo Co. Ltd. Human 26S proteasome subunit components

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002564A1 (en) * 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846810A (en) * 1994-10-28 1998-12-08 Kyowa Hakko Kogyo Co. Ltd. Human 26S proteasome subunit components
WO1998033888A1 (en) * 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CORREALE P ET AL: "Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 161, 1998, pages 3186 - 3194, XP002975760, ISSN: 0022-1767 *
SCHMIDT WALTER ET AL: "Cell-free tumor antigen peptide-based cancer vaccines", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 94, no. 7, 1997, pages 3262 - 3267, XP002168512, ISSN: 0027-8424 *
See also references of WO0197827A1 *
TJOA B A ET AL: "PROGRESS IN ACTIVE SPECIFIC IMMUNOTHERAPY OF PROSTATE CANCER", SEMINARS IN SURGICAL ONCOLOGY, vol. 18, no. 1, 2000, pages 80 - 87, XP000915524, ISSN: 8756-0437 *

Also Published As

Publication number Publication date
AU2001275490A1 (en) 2002-01-02
WO2001097827A1 (en) 2001-12-27
EP1303287A1 (en) 2003-04-23

Similar Documents

Publication Publication Date Title
ZA200108258B (en) Methods of inducing cancer cell death and tumor regression.
AU7924501A (en) Progenitor cells and methods and uses related thereto
PL335348A1 (en) Compounds for use in prostatic carcinoma immunotherapy and methods using them
AU2003217304A1 (en) Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
AU2001278070A1 (en) Basal cell markers in breast cancer and uses thereof
IL153970A0 (en) Promyostatin peptides and methods of using same
AU3869400A (en) Human cancer associated gene sequences and polypeptides
AU7524601A (en) T cell receptor fusions and conjugates and methods of use thereof
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1319178A4 (en) Method of identifying cancer markers and uses therefor in the diagnosis of cancer
EP1404366A4 (en) Combination therapy of gamma-interferon and b cell specific antibodies
EE9900179A (en) Use of conjugates in prostate cancer drugs
IL206604A0 (en) Transmembrane protein expressed in prostate cancer
MXPA03003011A (en) Methods of inducing cancer cell death and tumor regression.
HUP0104568A3 (en) Human prostatic cell lines for cancer treatment
AU2002243314A1 (en) Immunogenic cancer peptides and uses thereof
EP1303287A4 (en) Mhc peptides over-expressed on prostate cancer cells and methods of use
WO2003026494A3 (en) Galectins-1-and-4 in tumor development
PL371202A1 (en) Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
AU6111800A (en) 26 human prostate and prostate cancer associated proteins
IL148323A0 (en) Prostatic cell line and use thereof to obtain an established prostatic cancer in an animal
AU2002227272A1 (en) Ovarian tumor antigen and methods of use therefor
AU7832700A (en) Ovarian tumor antigen and methods of use therefor
PL357906A1 (en) Combination of carboxyalkylethers with antihypertensives and pharmaceutical use
AU2001250051A1 (en) Use of igf-i, igfbp-3 and psa to predict the risk of prostate cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030116

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/47 B

Ipc: 7C 12N 5/08 B

Ipc: 7C 12N 5/06 B

Ipc: 7C 07K 16/00 B

Ipc: 7C 07K 7/00 B

Ipc: 7A 01N 63/00 B

Ipc: 7A 61K 39/00 B

Ipc: 7A 61K 39/395 B

Ipc: 7A 61K 38/04 B

Ipc: 7A 61K 38/00 A

A4 Supplementary search report drawn up and despatched

Effective date: 20051223

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060715